Profile data is unavailable for this security.
About the company
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
- Revenue in USD (TTM)199.19m
- Net income in USD-631.48m
- Incorporated2021
- Employees560.00
- Location23andMe Holding Co.349 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 938-6300
- Fax+1 (302) 636-5454
- Websitehttps://investors.23andme.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Burning Rock Biotech Ltd (ADR) | 70.49m | -78.37m | 36.21m | 786.00 | -- | 0.3858 | -- | 0.5137 | -48.64 | -48.64 | 12.50 | 9.15 | 0.4331 | 1.97 | 2.68 | 89,686.04 | -48.15 | -37.09 | -65.09 | -45.29 | 67.71 | 70.02 | -111.18 | -123.88 | 2.85 | -- | 0.00 | -- | -4.58 | 20.81 | 32.69 | -- | -17.61 | -- |
| Exagen Inc | 56.66m | -17.31m | 48.51m | 174.00 | -- | 2.76 | -- | 0.8561 | -0.9689 | -0.9689 | 3.16 | 1.01 | 0.9986 | -- | 4.06 | 325,632.20 | -30.51 | -30.21 | -36.28 | -33.75 | 59.13 | 54.86 | -30.56 | -55.36 | -- | -7.08 | 0.5397 | -- | 15.33 | 10.13 | 50.01 | -- | 33.00 | -- |
| CRYO-CELL International, Inc. | 31.84m | -8.93m | 75.22m | 82.00 | -- | -- | -- | 2.36 | -1.08 | -1.08 | 3.86 | -1.19 | 0.4798 | 9.35 | 4.78 | 388,274.30 | -13.45 | 0.4686 | -18.45 | 0.7099 | 73.66 | 70.09 | -28.04 | 0.8133 | 0.5699 | -- | -- | -- | 3.32 | 1.41 | -443.57 | -- | 60.30 | -- |
| Cardiff Lexington Corp | 7.22m | -2.84m | 97.74m | 10.00 | 0.7895 | -- | -- | 13.54 | 8.23 | 3.61 | 0.9605 | 0.5838 | 0.3436 | -- | 0.542 | 722,096.00 | -9.27 | -- | -25.14 | -- | 49.32 | 62.01 | -26.98 | -- | -- | -0.0099 | 0.4916 | -- | -- | 39.71 | -- | -- | -- | -- |
| 23andMe Holding Co. | 199.19m | -631.48m | 113.50m | 560.00 | -- | 16.61 | -- | 0.5698 | -1.31 | -1.31 | 0.4112 | 0.2836 | 0.3215 | 8.28 | 76.27 | 355,692.80 | -101.91 | -- | -130.54 | -- | 44.79 | 46.35 | -317.03 | -121.63 | 1.43 | -- | 0.00 | -- | -26.66 | -13.01 | -113.92 | -- | -19.09 | -- |
| American Oncology Network Inc | 1.46bn | -16.08m | 130.74m | 1.53k | -- | -- | -- | 0.0896 | -1.95 | -1.95 | 91.57 | 1.87 | 3.52 | 28.83 | 10.64 | 956,595.40 | -19.18 | -- | -39.16 | -- | 4.99 | -- | -5.45 | -- | 1.09 | -10.85 | 0.6438 | -- | 11.27 | -- | -- | -- | -- | -- |
| American Well Corp | 254.04m | -214.08m | 135.58m | 1.10k | -- | 0.4019 | -- | 0.5337 | -14.54 | -14.54 | 17.22 | 22.02 | 0.4545 | 26.31 | 3.74 | 230,104.20 | -38.46 | -28.25 | -49.63 | -32.66 | 34.80 | 40.51 | -84.63 | -121.27 | 2.88 | -- | 0.00 | -- | -6.55 | 17.85 | -149.66 | -- | 51.49 | -- |
| Zomedica Corp | 26.08m | -55.99m | 137.19m | 144.00 | -- | 0.6573 | -- | 5.26 | -0.0571 | -0.0571 | 0.0266 | 0.213 | 0.1054 | 1.79 | 12.84 | 181,090.30 | -22.64 | -14.03 | -23.35 | -14.45 | 68.70 | -- | -214.70 | -220.98 | 10.68 | -- | 0.00 | -- | 33.05 | -- | -102.93 | -- | 89.85 | -- |
| Longduoduo Co Ltd | 7.39m | 1.26m | 154.53m | 49.00 | 123.09 | 219.96 | 105.46 | 20.91 | 0.0418 | 0.0418 | 0.2463 | 0.0234 | 4.17 | 422.80 | 61.99 | 150,812.90 | 76.89 | -- | 1,467.79 | -- | 97.65 | -- | 18.45 | -- | 1.31 | -- | 0.00 | -- | 93.52 | -- | 3,311.69 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 15.57m | 4.59% |
| Euclidean Capital LLCas of 30 Jun 2024 | 10.24m | 3.02% |
| Millennium Management LLCas of 30 Jun 2024 | 4.94m | 1.46% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.53m | 1.34% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 4.23m | 1.25% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.22m | 1.24% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 2.36m | 0.70% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 2.32m | 0.68% |
| Wittenberg Investment Management, Inc.as of 30 Jun 2024 | 2.31m | 0.68% |
| Jane Street Capital LLCas of 30 Jun 2024 | 2.29m | 0.67% |
